PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30964194-10 2019 The cytoprotective effects of SDX resulted from a reduction in a) ROS production, b) neo-synthesis and release of pro-inflammatory cytokines (TNFalpha, IL1, IL6, IL8), c) DNA damage induced by MGO or IR. glucuronyl glucosamine glycan sulfate 30-33 interleukin 6 Homo sapiens 157-160 19218094-7 2009 Sulodexide caused the inhibition of the intracellular generation of free radicals in a dose-dependent manner (maximally by 32%, P < 0.01), as well as the inhibition of MCP-1 (maximally by 60%, P < 0.001) and IL-6 (maximally by 69%, P < 0.01). glucuronyl glucosamine glycan sulfate 0-10 interleukin 6 Homo sapiens 214-218 34075143-12 2021 Additionally, Sulodexide decreases the secretion of IL6 and VEGF-A from senescent HREC and increases their TEER. glucuronyl glucosamine glycan sulfate 14-24 interleukin 6 Homo sapiens 52-55 30959503-11 2019 SUL reduced the uremic serum-induced secretion of all solutes: IL6 -24%, p < 0.05; ICAM-1 -43%, p < 0.01; VEGF -38%, p < 0.01; vWF -23%, p < 0.01; t-PA -49%, p < 0.01, and MMP9 -25%, p < 0.05. glucuronyl glucosamine glycan sulfate 0-3 interleukin 6 Homo sapiens 63-66 26044841-12 2015 Synthesis of IL-6 was lower in HVEC exposed in vitro to serum collected at the end of SUL treatment: 1.02+-0.31 ng/mug cell protein vs. 1.32+-0.41 ng/mug cell protein before SUL treatment. glucuronyl glucosamine glycan sulfate 86-89 interleukin 6 Homo sapiens 13-17 26868135-9 2016 In the supernatants obtained after cell incubation with serum from sulodexide treated patients, the increase in concentrations of IL-6, MCP-1 and ICAM-1 was significantly less than the control. glucuronyl glucosamine glycan sulfate 67-77 interleukin 6 Homo sapiens 130-134 27941341-7 2016 Sulodexide (0.5 LRU/mL) reduced atherosclerotic serum-induced increased expression of genes for IL-6 (-32%), VCAM-1 (-20%) and VWF (-42%), and lowered secretion of these molecules: IL-6 (-27%), VCAM-1(-27%), VWF (-25%). glucuronyl glucosamine glycan sulfate 0-10 interleukin 6 Homo sapiens 96-100 27941341-7 2016 Sulodexide (0.5 LRU/mL) reduced atherosclerotic serum-induced increased expression of genes for IL-6 (-32%), VCAM-1 (-20%) and VWF (-42%), and lowered secretion of these molecules: IL-6 (-27%), VCAM-1(-27%), VWF (-25%). glucuronyl glucosamine glycan sulfate 0-10 interleukin 6 Homo sapiens 181-185 27941341-8 2016 Sulodexide also reduced, in a dose- dependent manner, secretion of IL6 from unstimulated and stimulated with IL-1 endothelial cells. glucuronyl glucosamine glycan sulfate 0-10 interleukin 6 Homo sapiens 67-70